Deutsches Krebsforschungszentrum (DKFZ)

Advancing CNS tumor diagnostics with expanded DNA methylation-based classification (2026) Sill M, Schrimpf D, Patel A, Sturm D, Jäger N, Sievers P, Schweizer L, et al. Journal article MR Neurography in Children and Adolescents (2026) Preisner F, Garbade SF, Grünert SC, Schwarz D, Jende JM, Kurz FT, Sturm V, et al. Journal article COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma (2026) Weichenthal M, Debus D, Zimmer L, Wasielewski Iv, Meier F, Tüting T, Heppt M, et al. Journal article Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer (2026) Billaud A, Figlioli G, Mooser C, Casamassima I, Azzoni V, Srivatsa J, Colombo M, et al. Journal article Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy (2026) Dugas-Breit S, Forschner A, Erdmann M, Gutzmer R, Kähler KC, Holst I, Brekner A, et al. Journal article Evaluation of 7 Tesla pTx Body Coils Regarding Transmit and Receive Performance (2026) Grimm JA, Kraff O, May MW, Lutz M, Orzada S, Fiedler TM, Moeller S, et al. Journal article IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial (2026) Bunse L, Lindner K, Wick A, Freitag A, Lanz LM, Edelmann D, Suwala A, et al. Journal article Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals (2026) Neuen BL, Major RW, Grams ME, Sang Y, Coresh J, Ballew SH, Surapaneni A, et al. Journal article CT Reconstruction from Dual-View Depth Images and Topograms for Prospective Risk Minimization (2026) Mosig D, Serra Juhé A, Liu C, Oelze P, Lell M, Kachelrieß M, Maier A Conference contribution, Conference Contribution Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial (Nature Medicine, (2026), 10.1038/s41591-026-04455-x) (2026) Wermke M, Ochsenreither S, Jaeger D, Becker H, Bleckmann A, Bozorgmehr F, Chatterjee M, et al. Journal article, Erratum